In February 2015, the company submitted the investigational new drug (IND) application for Actimmune in the treatment of FA. The company has also announced plans to initiate a
Further to this deal, Celgene will purchase Mesoblast stock and hold a six-month right of first refusal to certain disease fields. As part of the agreement, Celgene will
Under the deal, the data will also be used to inform target selection, target validation, indication selection and repositioning. The deal will see Genomics partner with Eisai’s new
Currently, the company has multiple Phase III trials underway evaluating ADS-5102 for this indication, which currently has no FDA-approved treatment options. ADS-5102 (amantadine HCl) is a high dose,
At the new facility, the company will produce both Penfill cartridges and FlexPen prefilled insulin injection pens for the Russian market. Located in Technopark Grabtsevo in the Kaluga
The company’s US unit Eisai employs about 1,800 people and its operations include research and development, manufacturing, sales and marketing and administrative functions. Eisai chairman and CEO Yuji
The deal is part of Cipla’s front-end strategy and will expedite its product registrations in Brazil. Subject to certain closing deliverables, the transaction is expected to be completed
The company’s lead compound, cabozantinib, inhibits the activity of multiple tyrosine kinases including MET, VEGFRs and RET. Currently, cabozantinib is being evaluated in an ongoing Phase III METEOR
This monoclonal antibody is being examined for the prevention of lower respiratory tract illness (LRTI) caused by respiratory syncytial virus (RSV) in infants and young children. The company
Development of the LIMITX is currently being supported by a grant from the National Institute on Drug Abuse of the National Institutes of Health (NIH) to develop an
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.